You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202171 - 202180 of 207714 results
  1. Accessible Balance and Falls Prevention Exercise Tool Across the Continuum of Car

    SBC: BLUE MARBLE REHAB INC            Topic: NIA

    DESCRIPTION (provided by applicant): Objective: This Phase 1 SBIR proposes to optimize the interface and interaction of a digital translation of Evidence Based Falls Prevention programs for use across the continuum of care and community living that affordseasy adoption, adherence and monitoring of falls prevention exercises for all stakeholders including those with limited technical experience. Pu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A biomarker of aging as a predictor of kidney transplant function

    SBC: HEALTHSPAN DIAGNOSTICS, LLC            Topic: NIA

    ABSTRACT The number of kidney transplant candidates on the waiting list continues to increase each year, while the number of kidney donations remains stagnant. The enduring donor shortage compels clinicians to use kidneys from marginal donors, referred toas expanded criteria donors (ECD). ECD kidneys, obtained primarily from older donors, have a higher risk of delayed graft function and graft loss ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Compounds for Reducing Brain A-Beta Levels via Enhanced Systemic Clearance

    SBC: AKSTON BIOSCIENCES CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by progressively worsening dementia eventually leading to death. It affects over five million people in the United States and costs the healthcare system over 200 billion per year. Currently there is no available therapy for slowing, reversing or preventing the disease. There is strong evidence suggesting that AD ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel NMDA-targeted Therapy for Alzheimer's Disease

    SBC: Panorama Research Incorporated            Topic: NIA

    Abstract Memantine, an aminoadamantane, is approved to treat moderate-to-severe Alzheimer's disease in the US and in Europe. Memantine selectively inhibits abnormally active N-methyl-D-aspartate-type glutamate receptor (NMDAR) channels, while preserving normal glutamate activity and physiological neuronal function (Lipton, 2006; Lipton, 2007a,b). Pathological NMDA receptor activity is furthe ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of a novel computer-based test for early detection of Alzheimer's

    SBC: Neurotrack Technologies, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease currently affects an estimated 5.4 million Americans, and this number is expected to grow significantly in the coming decade. A critical and ultimate goal of Alzheimer's disease research is to improve methods of early diagnosis, so that patients can be identified sooner and, therefore, obtain greater advantage from available therap ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Potassium Level Monitoring System

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NIA

    DESCRIPTION (provided by applicant): Advanced Medical Electronics (AME) and our partners propose a minimally-invasive system for continuous monitoring of potassium. Measurement of blood levels of potassium is important in clinical medicine. Abnormalities of potassium, common in heart and kidney disease, can be aggravated by many medications used to treat these disorders leading to arrhythmias and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes.

    SBC: Mycosynthetix, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Title: Fungal Metabolites as Novel Anthelmintics against Soil-Transmitted Helminthes Project Summary/Abstract It is estimated that over 2 billion people worldwide are suffering from complications due to infections withsoil transmitted helminthes (STHs), but very little research is being conducted by human health pharmaceutical companies. In the USA, it is estim ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Antifungal Compound Discovery from Metagenomes

    SBC: LUCIGEN CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): There is societal need for new compounds in our arsenal of defenses against fungal pathogens, many of which are increasingly resistant to existing therapeutics. The best possible source for new antifungal compounds withpotentially novel mechanisms of action is within natural environments, particularly soils, which have the greatest diversity of microbial life. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Viru

    SBC: Somagenics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis D virus (HDV) infection is the most severe type of viral hepatitis, often causing accelerated liver damage that leads to end-stage liver disease. About 10-15 million individuals are infected by HDV worldwide.The absence of an effective treatment for acute forms of the disease and the limited efficacy of current treatments for the chronic infection jus ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. XHA-A Novel Tolerance Therapeutic for Allergic Rhinitis

    SBC: VIRTICI LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to extend the development of a novel compound that can reprogram memory T lymphocytes to induce tolerance in allergic rhinitis (AR). AR is one of the most common chronic diseases in the United States (US) and is estimated to affect more than 50 million people [1,2]. As a result, the annual US economic burden of AR exceeds 12 billio ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government